Hepatic Encephalopathy Treatment Market Report and Forecast 2024-2032

Hepatic Encephalopathy Treatment Market Outlook

The hepatic encephalopathy treatment market size was valued at USD 1.6 billion in 2023, driven by the rising incidence of liver cirrhosis across the 7 major markets. The market is expected to grow at a CAGR of 5.7% during the forecast period of 2024-2032, with the values likely to rise from USD 1.7 billion in 2024 to USD 2.6 billion by 2032.

Hepatic Encephalopathy Treatment: Introduction

Hepatic encephalopathy is a temporary neurological disorder that occurs due to a severe liver disease. The damaged liver fails to clear out the toxins effectively and toxins build up reaches the brain through the blood stream. It causes cognitive impairment and affects brain function. Hepatic encephalopathy is commonly managed by antibiotics and laxatives. However, the treatment may vary depending upon the symptoms and overall health of the patient.

Hepatic Encephalopathy Treatment Market Analysis

The hepatic encephalopathy treatment market demand is mostly driven by the increasing prevalence of liver-associated diseases which include liver cirrhosis, hepatitis, and fatty liver.

Nonabsorbable disaccharides, such as lactulose or lactitol, are considered as the first in-line treatment for the condition. They function by lowering the absorption of ammonia in the body. Another commonly used treatment method is the use of antibiotics. They are used to alter the gut microbiota to create a more favourable microbiome that leads to decreased endogenous bacterial production of ammonia. Rifaximin, Neomycin and Metronizadole are frequently prescribed to treat the condition.

Dietary treatment alternatives that naturally lower down the ammonia levels in the body can also be applied. Using intravenous L-ornithine-L-aspartate has been proven helpful in lowering the severity of the condition in some patients. If the condition persists due to complete liver damage, then liver transplant is the last alternative recommended by healthcare professionals.

Apart from pharmaceuticals, the hepatic encephalopathy treatment market value is also driven by the rising advancements in diagnostics. Tests like electroencephalography are used to determine the severity of the condition and facilitate effective treatment based on it.

Hepatic Encephalopathy Treatment Market Segmentation

Market Breakup by Drug Class

• Antibiotics

• Laxatives

• L-ornithine

• L-aspartate

• Others

Market Breakup by Diagnosis

• Blood Tests

• CT Scan

• Liver Functioning Tests (LFT)

• Others

Market Breakup by Treatment

• Medication

• Surgery

• Others

Market Breakup by Route of Administration

• Oral

• Injectable

• Intravenous

• Rectal

• Others

Market Breakup by End User

• Hospitals

• Homecare

• Speciality Clinics

• Others

Market Breakup by Distribution Channels

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

• Others

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

Hepatic Encephalopathy Treatment Market Overview

The United States has been proactive in mitigating the rising burden of liver diseases. The region has held a substantial percentage of the hepatic encephalopathy treatment market share. With increasing drug development and other treatment alternatives, there has been significant emphasis on educating the population on identifying the early stages of liver damage. This has been made possible through awareness campaigns and initiatives set up by government as well as private institutions. In July 2023, the World Health Organization launched “One Life, One Liver” campaign, aimed at protecting liver health.

Alcohol consumption, obesity and sedentary lifestyle are major factors contributing to liver diseases. Hence, Europe is also a significant player of the hepatic encephalopathy treatment market. With well-equipped medical infrastructure and staff, it can pioneer the treatment market by bringing groundbreaking innovations to improve the efficacy of medicines.

With a high percentage of geriatric population, the Asia Pacific region is expected to witness rapid hepatic encephalopathy treatment market growth in the coming years. The region has been experiencing major mergers and acquisitions among impactful companies, which are anticipated to fuel market growth. With an influx of foreign investments, the medical infrastructure is also improving.

Hepatic Encephalopathy Treatment Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Salix Pharmaceuticals

• Mallinckrodt plc.

• Merck & Co., Inc.

• Bausch Health

• Takeda Pharmaceutical Company Limited

• Johnson & Johnson Services, Inc.

• Eisai Co., Ltd

• AbbVie Inc.

• Hikma Pharmaceuticals PLC

• Vedanta Biosciences

• Patricia Bloom

• Umecrine Cognition

• Axcella Health Inc.

• Pfizer Inc.

• Rebiotix

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report